Serum Level of suPAR and YKL-40, a New Biomarker in Patients with Acute Myocardial Infarction?

Basit Öğe Kaydı
dc.authoridAlpay Arıbaş: 0000-0003-0437-3237
dc.authoridFatma Hümeyra Yerlikaya: 0000-0002-4107-5389
dc.contributor.authorArıbaş, Alpay
dc.contributor.authorCan, Ümmügülsüm
dc.contributor.authorYerlikaya, Fatma Hümeyra
dc.contributor.authorToker, Aysun
dc.contributor.authorAkbuğa, Kürşat
dc.date.accessioned2020-01-18T21:02:56Z
dc.date.available2020-01-18T21:02:56Z
dc.date.issued2015
dc.departmentNEÜ, Meram Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Kardiyoloji Anabilim Dalıen_US
dc.description.abstractIntroduction: Low grade inflammation plays an important role in the several development process of coronary artery disease. The soluble urokinase plasminogen activator receptor (suPAR) and chitinase 3-like protein 1 (YKL-40) are the new potential biomarkers of inflammation. We intended to test the hypothesis whether the inflammatory biomarker YKL-40 alone or in combination with suPAR could be the new diagnostic biomarkers for acute myocardial infarction (AMI). Material and Methods: Fifty-five patients with AMI and seventy control subjects were included in the study. The diagnosis of AMI was based on the current 3rd standard universal definition criteria. Serum YKL-40 and suPAR levels were measured at the first and second days of AMI by using ELİSA method. Results: Serum YKL-40 levels were significantly higher in the first (69.10 16.58 ng/mL) and second day (60.64 16.01 ng/mL) of AMI patients than those of the control subjects (37.11 4.30 ng/mL) (p0.001). Serum YKL-40 levels in the first day of AMI patients also were significantly higher than those of second day of AMI patients (p0.01). Serum suPAR were significantly higher in the first (6.58 3.24 ng/mL) and second day (5.86 4.56 ng/mL) of AMI patients than those of the control subjects (2.26 1.92 ng/mL) (p0.001). Conclusion: Serum suPAR and YKL-40 can be considered strong inflammatory markers of AMI. We concluded that serum suPAR and YKL-40 levels at the first day and second day of AMI could be used as a clinically useful marker for diagnosis of AMI.en_US
dc.identifier.citationArıbaş A., Can, Ü., Yerlikaya, F. H., Toker, A., Akbuğa, K. (2015). Serum level of suPAR and YKL-40, a new biomarker in patients with acute myocardial infarction?. Acta Medica Anatolia, 3, 4, 137-143.
dc.identifier.endpage143en_US
dc.identifier.issn2148-2357en_US
dc.identifier.issn2148-2357en_US
dc.identifier.issue4en_US
dc.identifier.startpage137en_US
dc.identifier.urihttps://app.trdizin.gov.tr/makale/TVRreU5qTTBOQT09/serum-level-of-supar-and-ykl-40-a-new-biomarker-in-patients-with-acute-myocardial-infarction-
dc.identifier.urihttps://hdl.handle.net/20.500.12452/1369
dc.identifier.volume3en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofActa Medica Anatoliaen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US]
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectInflammationen_US
dc.subjectThe inflammatory biomarkeren_US
dc.subjectIschemic heart diseaseen_US
dc.titleSerum Level of suPAR and YKL-40, a New Biomarker in Patients with Acute Myocardial Infarction?en_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
a513de49-4a9f-4089-bbdf-cd60b1126d31.pdf
Boyut:
404.19 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin (Full Text)
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu